Olanzapine is used as a 5-HT2/D2 antagonist for the treatment of schizophrenia; it is indicated for the management of schizophrenia, bipolar mania, and agitation associated with dementia; it alleviates both positive symptoms (e.g., delusions, hallucinations, thought disorder, hostility, and suspiciousness) and negative symptoms (e.g., blunted affect, emotional and social withdrawal, and poverty of speech) of schizophrenia, as well as secondary affective symptoms commonly associated with schizophrenia and related disorders.